Future Tech investment articles generated using Ai technology : Today we added to an "anchor stock" Royalty Pharma (RPRX) as it monetizes more assets and announces it will buy it's own shares!

Since September 2024, when we bought RPRX shares, (see our initial post next)

Royalty Pharma (RPRX) has undertaken several significant initiatives:

Financial Transactions and Investments:

November 4, 2024: Entered into a $350 million synthetic royalty funding agreement with Syndax Pharmaceuticals, based on U.S. net sales of Niktimvo (axatilimab-csfr).
November 7, 2024: Agreed to acquire a synthetic royalty on U.S. sales of Geron Corporation’s Rytelo for $125 million in cash upfront.
January 29, 2025: Monetized the remaining fixed payments on the MorphoSys Development Funding Bonds for $511 million in upfront cash.

Corporate Developments:

January 10, 2025: Announced the acquisition of its external manager and initiated a $3 billion share repurchase program, marking a transformative step in the company's evolution.

Financial Performance:

November 6, 2024: Reported third-quarter 2024 financial results and raised full-year 2024 guidance for Portfolio Receipts.
January 28, 2025: Scheduled to announce fourth-quarter and full-year 2024 financial results on February 11, 2025.

Dividend Announcement:

January 9, 2025: Declared a first-quarter 2025 dividend of $0.22 per Class A ordinary share, reflecting a 5% increase over the previous quarter's dividend.

These actions underscore Royalty Pharma's commitment to strategic investments and shareholder value enhancement.

Recent Developments at Royalty Pharma

Thursday, February 6, 2025